Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United Kingdom

Jason Lester (Jason.Lester2@wales.nhs.uk)  
Swansea Bay University Health Board, Port Talbot, United Kingdom  
https://orcid.org/0000-0002-2311-070X

Carles Escriu  
Clatterbridge Cancer Centre NHS Foundation Trust

Sarah Khan  
Nottingham University Hospitals NHS Trust

Emma Hudson  
Velindre University NHS Trust

Talal Mansy  
South Tees Hospitals NHS Foundation Trust

Andrew Conn  
Bradford Teaching Hospitals NHS Foundation Trust

Samuel Chan  
York Teaching Hospital NHS Foundation Trust

Ceri Powell  
York Teaching Hospital NHS Foundation Trust

Juliet Brock  
Brighton and Sussex University Hospitals NHS Trust

John Conibear  
Barts Health NHS Trust

Lauren Nelless  
SVMPharma Ltd

Vaneet Nayar  
SVMPharma Ltd

Xiaohui Zhuo  
EMD Serono Research and Development Institute

Adeline Durand  
Merck Serono Ltd

Amerah Amin
Research article

Keywords: advanced or metastatic non-small cell lung cancer, real-world outcomes, real-world treatment patterns

DOI: https://doi.org/10.21203/rs.3.rs-74772/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment patterns and clinical outcomes in aNSCLC in the United Kingdom.

**Methods:** Electronic prescribing records of treatment-naive patients starting first-line (1L) treatment for aNSCLC between June 2016 and March 2018 (follow-up until December 2018) in the United Kingdom were assessed retrospectively. Patient characteristics and treatment patterns were analyzed descriptively. Outcomes assessed included overall survival (OS), time to treatment discontinuation, time to next treatment, and real-world tumor response.

**Results:** In all, 1003 patients were evaluated (median age, 68 years [range, 28-93 years]; 53.9% male). Use of 1L IO monotherapy (0%-25.9%) and targeted therapy (11.8%-15.9%) increased during the study period, but chemotherapy remained the most common 1L treatment at all time points (88.2%-58.2%). Median OS was 9.5 months (95% CI, 8.8-10.7 months) for all patients, 8.1 months (95% CI, 7.4-8.9 months) with chemotherapy, 14.0 months (95% CI, 10.7-20.6 months) with IO monotherapy, and 20.2 months (95% CI, 16.0-30.5 months) with targeted therapy. In the 28.6% of patients who received second-line treatment, IO monotherapy was the most common drug class (used in 51.6%).

**Conclusions:** Although use of 1L IO monotherapy for aNSCLC increased in the United Kingdom during the study period, most patients received 1L chemotherapy. An OS benefit for first-line IO monotherapy vs chemotherapy was observed but was numerically smaller than that reported in clinical trials. Targeted therapy was associated with the longest OS, highlighting the need for improved treatment options for tumors lacking targetable mutations.

Background

Lung cancer is the leading cause of cancer-related death in the United Kingdom [1]. Non-small cell lung cancer (NSCLC) accounts for 80%-85% of lung cancers in the United Kingdom [2], and most patients have advanced disease at initial diagnosis [3]. The use of chemotherapy to treat advanced NSCLC (aNSCLC) has increased steadily over time [4]. Platinum-based doublet therapy remains a first-line (1L) standard of care, although it provides modest overall survival (OS) benefit and is associated with significant toxicity [5–7]. In the United Kingdom, the 1-year OS rate in patients diagnosed with aNSCLC is approximately 19%, and rates have improved very little over the past 40 years [8].

In a subgroup of aNSCLC, treatment paradigms changed dramatically with the advent of targeted therapies that inhibit oncogenic drivers, namely molecular alterations in genes encoding epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) [9]. Treatment options further improved with the development of immuno-oncology (IO) therapies that can activate antitumor immune responses by blocking the interaction between programmed cell death protein 1 (PD-1) and its ligand (PD-L1), which showed prolonged overall survival vs chemotherapy [10–12].
United Kingdom, the IO monotherapy pembrolizumab was made initially available through Early Access to Medicines Schemes; from 10 March 2016 to 31 January 2017 as a 1L treatment, and from 10 March 2016 to 29 July 2016 as a second-line (2L) treatment [13]. Subsequently, and similarly to other countries, IO monotherapy for aNSCLC then received positive recommendations (from the UK National Institute for Health and Care Excellence) as a 2L treatment, starting with pembrolizumab in January 2017 and followed by nivolumab and atezolizumab in November 2017 and May 2018, respectively [14–16]. Following the publication of the UK National Institute for Health and Care Excellence (NICE) appraisal for 1L pembrolizumab monotherapy for aNSCLC in July 2018, UK guidelines for 1L treatment were updated to recommend that patients whose tumors had ≥ 50% PD-L1 expression and did not harbor molecular alterations in EGFR or ALK should receive IO monotherapy (pembrolizumab); targeted agents were recommended for patients whose tumors tested positive for EFGFR, ALK and ROS1 alterations, and platinum-based chemotherapy was recommended for other patients [17]. In June 2019, NICE approved 1L IO therapies in combination with chemotherapy, irrespective of PD-L1 status [18–20].

Data gathered from real-world investigations can complement findings from randomized clinical trials and provide an overview of treatment patterns and outcomes in clinical practice [21]. In a systematic review of real-world studies in aNSCLC published between 2010 and 2017, including various European studies, chemotherapy was found to be the most common treatment in the 1L, 2L, and third-line (3L) treatment settings [22]. In addition, a UK-based study analyzed all patients diagnosed with NSCLC but did not focus on treatment [23]. However, only limited data are available to assess the impact of IO therapy on treatment patterns in aNSCLC.

Here, we report findings from a real-world study of treatment patterns and outcomes in UK patients with aNSCLC who received 1L treatment during the period when IO monotherapy was introduced. By using a representative network of UK treatment centers, we aimed to analyze data from approximately 10% of the annual incident population of patients with aNSCLC who were initiated on 1L treatment (Supplemental Fig. 1).

Methods

Aim, Study Design and Setting, and Data Sources

This was a retrospective, observational study of treatment-naive adults with aNSCLC who initiated 1L systemic anticancer therapy in the United Kingdom between June 1, 2016 and March 31, 2018, and who were followed until December 31, 2018. Identified patients were included sequentially from March 31, 2018, backward. Inclusion of 1000 patients from 10 sites was planned. Initial patient data were obtained via database abstraction from electronic prescribing records, which are widely used within hospitals in the UK and record all anticancer prescriptions dispensed to patients, including physician defined treatment lines and cycles. Subsequently, electronic prescribing record data from provisionally eligible patients were entered into electronic case report forms, which were sent to hospitals for supplementation using patient notes. On the basis of available information and the eligibility criteria below, patients were
included or excluded from the final analysis. Data was pseudonymized at source; hence, patient consent was not required.

**Eligibility Criteria**

Patients were included if they were aged ≥18 years and were diagnosed with advanced or metastatic NSCLC at the time of initiating 1L systemic anticancer treatment and had received no prior treatment for aNSCLC. Advanced disease was defined as ≥1 of the following: (1) physician-defined stage IV disease, (2) TNM staging with an M value of 1, (3) patient record identifying the location of metastatic disease, or (4) current or prior disease status containing a reference to advanced or metastatic disease. Patients were excluded if they had been enrolled in a clinical trial at any time during the study period or if required study data were missing.

**Statistical Analysis**

Patient and disease characteristics were collected at diagnosis and analyzed descriptively. Outcomes analyzed were: OS (interval between 1L treatment initiation and date of death from any cause); time to treatment discontinuation (TTD; interval between 1L treatment initiation and discontinuation for any reason, including death), which provides an indication of both progression-free survival and tolerability (ie, discontinuation due to progression or toxicity); time to next treatment (TtNT; interval between 1L treatment initiation and 2L treatment initiation or death), assessed to determine any benefit in treatment-free interval; and real-world tumor response (rwTR; analyzed as a surrogate for objective response rate [24]. Time to event outcomes (OS, TTD, and TtNT) were analyzed using the Kaplan-Meier method; patients who were event-free during the study observation period were censored on their last assessment date or at the study end date (whichever occurred first). For the analysis of TTD, in patients who discontinued treatment but were still alive, the treatment end date was recorded as the start date of the last treatment cycle because a definitive end date of the last cycle was not available, and the last cycle start date was the latest date when it was certain that treatment was continuing.

Data for baseline characteristics and patient outcomes were analyzed in the overall population and in discrete subgroups defined by 1L drug class, ie, IO monotherapy (anti–PD-1 or PD-L1 antibody), targeted therapy (inhibitor of EGFR, ALK, or ROS1), or chemotherapy (cytotoxics and other agents).

Analysis of treatment patterns included overall breakdown by drug class and regimen, overall treatment sequencing by drug class, and change in 1L use of drug classes over time. A regimen included all drugs used in each line of treatment.

**Results**

**Patients**

Of 1257 patients who were assessed for eligibility, 1003 treatment-naive patients from 9 sites (Supplemental Table 1) who initiated 1L therapy for aNSCLC between June 1, 2016, and March 31, 2018,
were included in the study population (Table 1). Patient data were not obtained from 1 of 10 planned sites because of capacity issues; 2 sites (Nottingham University Hospitals NHS Trust and the Clatterbridge Cancer Centre NHS Foundation Trust) contributed 56% of patients. In the study population, the median age was 68 years (range, 28–93 years), 53.9% were male, Eastern Cooperative Oncology Group performance status score was 0–1 in 75.7% and ≥2 in 24.3%, and tumor histology was non-squamous in 63.9%, squamous in 24.2%, and unknown in 11.9% (Table 2). All patients had metastatic disease at diagnosis.

Table 1
Summary of Patient Numbers in the Study Population and Reasons for Exclusion (Study Attrition)

| Patients                                      | n   | %  |
|-----------------------------------------------|-----|-----|
| Adults who received 1L treatment for NSCLC    | 1257| –   |
| Excluded patients                             | 254 | 100 |
| NSCLC not advanced or metastatic at diagnosis | 151 | 59.4|
| Treatment started outside of study period     | 47  | 18.5|
| ECOG PS score missing                         | 15  | 5.9 |
| Randomized trial participant                  | 9   | 3.5 |
| Response data missing                         | 8   | 3.1 |
| Never received treatment                      | 7   | 2.8 |
| Duplicate patient                             | 5   | 2.0 |
| Age missing                                   | 4   | 1.6 |
| Sex missing                                   | 3   | 1.2 |
| Not NSCLC                                     | 2   | 0.8 |
| Date of death or last hospital follow-up missing | 1 | 0.4 |
| Histological diagnosis missing                | 1   | 0.4 |
| Diagnosis date unknown                        | 1   | 0.4 |
| Met inclusion criteria                         | 1003| –   |

1L, first line; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC, non-small cell lung cancer.
Table 2  
Patient Demographics in the Overall Population and in Subgroups Defined by 1L Drug Class Received

|                                | All patients (n = 1003) | 1L chemotherapy (n = 698) | 1L IO monotherapy (n = 179) | 1L targeted therapy (n = 126) |
|--------------------------------|-------------------------|---------------------------|-----------------------------|-------------------------------|
| **Proportion of study population, %** | 100 | 69.6 | 17.8 | 12.6 |
| **Median follow-up (range), months** | 9.2 (0.0-42.7) | 7.9 (0.0-42.7) | 12.7 (0.1–37.3) | 16.3 (0.1–37.1) |
| **Median age at diagnosis (range), years** | 68 (28–93) | 68 (28–88) | 67 (48–90) | 70 (32–93) |
| **Sex, n (%)**                   |               |                           |                             |                               |
| Male                            | 541 (53.9)    | 395 (56.6)                | 94 (52.5)                   | 52 (41.3)                     |
| Female                          | 462 (46.1)    | 303 (43.4)                | 85 (47.5)                   | 74 (58.7)                     |
| **Tumor histology, n (%)**      |               |                           |                             |                               |
| Adenocarcinoma                  | 635 (63.3)    | 387 (55.4)                | 131 (73.2)                  | 117 (92.9)                    |
| Squamous cell carcinoma         | 243 (24.2)    | 202 (28.9)                | 38 (21.2)                   | 3 (2.4)                       |
| Large cell carcinoma            | 6 (0.6)       | 4 (0.6)                   | 2 (1.1)                     | 0                             |
| Not specified                   | 119 (11.9)    | 105 (15.0)                | 8 (4.5)                     | 6 (4.8)                       |
| **TNM stage at diagnosis, n (%)** |       |                           |                             |                               |
| T                               |              |                           |                             |                               |
| T X-4                           | 938 (93.5)    | 647 (92.7)                | 170 (95.0)                  | 121 (96.0)                    |
| N/A                             | 65 (6.5)      | 51 (7.3)                  | 9 (5.0)                     | 5 (4.0)                       |
| N                               |              |                           |                             |                               |
| N X-3                           | 939 (93.6)    | 648 (92.8)                | 170 (95.0)                  | 121 (96.0)                    |

1L, first line; ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IO, immuno-oncology; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1.

\( ^a \) Includes 77 patients with clinician-defined stage IV NSCLC.

\( ^b \) Biomarker status was based either on hospital test results (documented) or treatment regimen (assumed, ie, patients who received an EGFR or ALK inhibitor were assumed to have a tumor harboring an *EGFR* or *ALK* mutation, and patients receiving IO therapy were assumed to have a PD-L1 + tumor).
### Treatment Patterns and Sequencing

|                          | All patients (n = 1003) | 1L chemotherapy (n = 698) | 1L IO monotherapy (n = 179) | 1L targeted therapy (n = 126) |
|--------------------------|--------------------------|---------------------------|-----------------------------|-------------------------------|
| N/A                      | 64 (6.4)                 | 50 (7.2)                  | 9 (5.0)                     | 5 (4.0)                       |
| M                        |                          |                           |                             |                               |
| M1a                      | 524 (52.2)               | 351 (50.3)                | 114 (63.7)                  | 59 (46.8)                     |
| M1a                      | 166 (16.6)               | 120 (17.2)                | 22 (12.3)                   | 24 (19.0)                     |
| M1b                      | 310 (30.9)               | 224 (32.1)                | 43 (24.0)                   | 43 (34.1)                     |
| M1c                      | 3 (0.3)                  | 3 (0.4)                   | 0                           | 0                             |
| **ECOG PS score at diagnosis, n (%)** |                       |                           |                             |                               |
| 0−1                      | 759 (75.7)               | 513 (73.5)                | 157 (87.7)                  | 89 (70.6)                     |
| 2+                       | 244 (24.3)               | 185 (26.5)                | 22 (12.3)                   | 37 (29.4)                     |
| **EGFR + status, n (%)** |                          |                           |                             |                               |
| Documented               | 19 (1.9)                 | 1 (0.1)                   | 0                           | 18 (14.3)                     |
| Assumed                  | 89 (8.9)                 | 0                         | 0                           | 89 (70.6)                     |
| **ALK + status, n (%)**  |                          |                           |                             |                               |
| Documented               | 2 (0.2)                  | 0                         | 0                           | 2 (1.6)                       |
| Assumed                  | 17 (1.7)                 | 0                         | 0                           | 17 (13.5)                     |
| **PD-L1 + status, n (%)**|                          |                           |                             |                               |
| Documented               | 10 (1.0)                 | 3 (0.4)                   | 7 (3.9)                     | 0                             |
| Assumed                  | 172 (17.1)               | 0                         | 172 (96.1)                  | 0                             |

1L, first line; ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IO, immuno-oncology; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1.

*a* Includes 77 patients with clinician-defined stage IV NSCLC.

*b* Biomarker status was based either on hospital test results (documented) or treatment regimen (assumed, ie, patients who received an EGFR or ALK inhibitor were assumed to have a tumor harboring an *EGFR* or *ALK* mutation, and patients receiving IO therapy were assumed to have a PD-L1 + tumor).
First-line treatment comprised chemotherapy in 698 patients (69.6%), IO monotherapy in 179 patients (17.8%), and targeted therapy in 126 patients (12.6%). Among chemotherapy-treated patients, 674 (96.6%) received platinum-based chemotherapy, and carboplatin-based doublet or triplet chemotherapy was the most commonly administered regimen (n = 499 [71.5% of chemotherapy-treated patients]; Table 3). Among patients who received 1L IO monotherapy or targeted therapy, pembrolizumab (n = 174 [97.2% of the 1L IO subgroup]) and afatinib (n = 67 [53.2% of the 1L targeted therapy subgroup]) were the most commonly administered agents, respectively. During the time period analyzed (June 2016 to March 2018), the proportions of patients receiving 1L IO monotherapy or targeted therapy increased (from 0–25.9% for IO therapy, and from 11.8–15.9% for targeted therapy), whereas the proportion of 1L chemotherapy-treated patients decreased (from 88.2–58.2%; Fig. 1).
### Table 3
First-Line and Second-Line Treatment Regimens

| Regimen                                | Patients, n (%) |          |          |
|----------------------------------------|-----------------|----------|----------|
|                                        | 1L therapy      | 2L therapy |
|                                        | (n = 1003)      | (n = 287) |
| **Chemotherapy**                       |                 |          |          |
| Carboplatin-based doublet or triplet therapy\(^a\) | 499 (49.8)      | 57 (19.9) |
| Carboplatin                            | 3 (0.3)         | 0        |
| Cisplatin-based doublet or triplet therapy\(^a\) | 172 (17.1)      | 7 (2.4)  |
| Docetaxel                              | 5 (0.5)         | 17 (5.9) |
| Docetaxel + nintedanib                | 4 (0.4)         | 16 (5.6) |
| Gemcitabine                            | 3 (0.3)         | 1 (0.3)  |
| Nintedanib                            | 0               | 1 (0.3)  |
| Paclitaxel                             | 0               | 4 (1.4)  |
| Vinorelbine                            | 3 (0.3)         | 1 (0.3)  |
| **Immuno-oncology therapy**            |                 |          |          |
| Atezolizumab                           | 0               | 32 (11.1) |
| Nivolumab                              | 5 (0.5)         | 20 (7.0) |
| Pembrolizumab                          | 174 (17.3)      | 96 (33.4) |
| **Targeted therapy\(^b\)**             |                 |          |          |
| Afatinib                               | 67 (6.7)        | 5 (1.7)  |
| Alectinib                              | 2 (0.2)         | 2 (0.7)  |
| Ceritinib                              | 6 (0.6)         | 3 (1.0)  |
| Crizotinib                             | 11 (1.1)        | 4 (1.4)  |

1L, first line; 2L, second line; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ROS, ROS proto-oncogene 1.

\(^a\) Triplet therapy indicates carboplatin (IV) + vinorelbine (IV) + vinorelbine (oral), cisplatin (IV) + vinorelbine (IV) + vinorelbine (oral), or cisplatin (IV) + etoposide (IV) + etoposide (oral).

\(^b\) EGFR, ALK, or ROS inhibitor.
| Regimen | Patients, n (%) |
|---------|----------------|
|         | 1L therapy (n = 1003) | 2L therapy (n = 287) |
| Erlotinib | 12 (1.2) | 5 (1.7) |
| Gefitinib | 24 (2.4) | 3 (1.0) |
| Osimertinib | 4 (0.4) | 13 (4.5) |

1L, first line; 2L, second line; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ROS, ROS proto-oncogene 1.

\( ^a \) Triplet therapy indicates carboplatin (IV) + vinorelbine (IV) + vinorelbine (oral), cisplatin (IV) + vinorelbine (IV) + vinorelbine (oral), or cisplatin (IV) + etoposide (IV) + etoposide (oral).

\( ^b \) EGFR, ALK, or ROS inhibitor.

In the overall population, 287 patients (28.6%) received 2L therapy, which was chemotherapy in 104 (36.2%), IO monotherapy in 148 (51.6%), and targeted therapy in 35 (12.2%; Table 3). The most common 2L therapy was pembrolizumab (n = 96 [33.4%]). The most common treatment sequence was 1L chemotherapy, followed by 2L IO monotherapy (n = 146 [20.9% of those who received 1L chemotherapy]) or 2L chemotherapy (n = 74 [10.6% of those who received 1L chemotherapy]; Supplemental Fig. 2). Of patients who had received 1L IO monotherapy, chemotherapy was the most common 2L treatment (n = 26 [14.5% of those who received 1L IO monotherapy]). Of patients who received 1L targeted therapy, targeted therapy was also the most commonly used 2L treatment class (n = 26 [20.6% of those who received 1L targeted therapy]).

Of 716 patients who did not receive 2L therapy, 77.0% died (88.7%, 56.3%, and 52.1% of those who had received 1L chemotherapy, IO monotherapy, or targeted therapy, respectively), 12.8% had ongoing 1L treatment (1.9%, 31.8%, and 36.5% of those who received 1L chemotherapy, IO monotherapy, or targeted therapy, respectively), and 10.2% stopped treatment and were still alive at the end of the study period (9.4%, 11.9%, and 11.5% of those who had received 1L chemotherapy, IO monotherapy, or targeted therapy, respectively; Supplemental Table 2).

Of the 287 patients who received 2L treatment, 51 subsequently received 3L treatment (5.1% of the total population or 17.8% of the 2L population [21.3%, excluding 47 patients who continued to receive 2L therapy at last follow-up]). Eleven patients received fourth-line (4L) therapy (1.1% of the total population or 21.6% of the 3L population [28.2%, excluding 12 patients who continued to receive 3L therapy at last follow-up]), and 1 patient received fifth-line therapy (0.1% of the total population or 9.1% of the 4L population [10.0%, excluding 1 patient who continued to receive 4L therapy at last follow-up]; Supplemental Fig. 2).

**Clinical Outcomes**
In the overall population, the median follow-up was 9.2 months (95% CI, 0-42.7 months), with a longer median follow-up in the IO monotherapy group (12.7 months, 95% CI, 0.1–37.3 months) and targeted therapy group (16.3 months, 95% CI, 0.1–37.1 months), and a shorter median follow-up in the chemotherapy group (7.9 months, 95% CI, 0-42.7 months) (Table 2). The median OS was 9.5 months (95% CI, 8.8–10.7 months; Fig. 2A) in the entire population. Within 1L subgroups defined by drug class, median OS was longest in patients who had received 1L targeted therapy (median 20.2 months [95% CI, 16.0–30.5 months]), followed by patients who had received 1L IO monotherapy (median 14.0 months [95% CI, 10.7–20.6 months]), and was shortest in patients who had received 1L chemotherapy (median 8.1 months [95% CI, 7.4–8.9 months]; Fig. 2B). In the overall population, median TTD from 1L was 2.1 months (95% CI, 2.1–2.3 months; Fig. 2C). Within subgroups, the median TTD was longest with 1L targeted therapy (median, 7.6 months [95% CI, 5.8–11.5 months]) and was 5.3 months (95% CI, 4.2–7.2 months) with 1L IO monotherapy and 2.1 months (95% CI, 1.8–2.1 months) with 1L chemotherapy (Fig. 2D). Median TtNT from 1L was 6.7 months (95% CI, 6.3–7.3 months) in the overall study population (Fig. 2E); in 1L subgroups, it was 13.6 months (95% CI, 10.7–18.8 months) with 1L targeted therapy, 8.9 months (95% CI, 7.5–15.8 months) with 1L IO monotherapy, and 5.9 months (95% CI, 5.3–6.3 months) with 1L chemotherapy (Fig. 2F).

In the overall population, 291 patients (29.0%) had an rwTR. Within 1L subgroups, rwTRs occurred in 187 (26.8%) of those who received 1L chemotherapy, 61 (34.1%) of those who received 1L IO monotherapy, and 43 (34.1%) of those who received 1L targeted therapy.

**Discussion**

In this retrospective study, we assessed real-world treatment patterns and outcomes in treatment-naive patients with aNSCLC who started 1L systemic anticancer therapy in the United Kingdom between June 2016 and March 2018. To our knowledge, this is the first large-scale UK study to report data in this setting. By obtaining data from more than 1000 patients treated at both tertiary cancer centers and district general hospitals, this study provides a robust and generalizable dataset describing real-world 1L treatment for aNSCLC. Patient characteristics in our study population are comparable to previous real-world UK studies in NSCLC [25, 26]. Our findings show that IO monotherapy has been adopted rapidly as 1L therapy following reimbursement approval in the United Kingdom, and although use of 1L chemotherapy decreased over the study period, chemotherapy remained the most common 1L treatment. IO therapy was the most commonly used 2L treatment, possibly reflecting the greater length of time these agents have been available to UK patients, the increased availability of IO agents in 2L and wider eligibility criteria and the fact that 2L chemotherapy is associated with modest benefit but substantial toxicity.

PD-L1 biomarker information was not recorded in our dataset; thus, it was not possible to assess the use of 1L IO monotherapy or chemotherapy with respect to PD-L1–positive status. It has been estimated previously that 23%-28% of patients with aNSCLC have tumor cell PD-L1 expression ≥ 50% [27, 28]. Given that 1L IO monotherapy usage in our analysis increased from 0–25.9% during study follow-up, it appears
that IO monotherapy may have been used in the vast majority of patients whose cancers have PD-L1 expression of ≥ 50%. Furthermore, excluding patients whose tumors harbored EGFR or ALK mutations (who are ineligible for pembrolizumab within the approved indication), 1L IO monotherapy was received in the final full quarter by 30.8% (41/133) of all patients, which is consistent with the incidence of PD-L1 tumor proportion score ≥ 50% reported in the KEYNOTE-024 trial (30.2% of all screened patients with PD-L1 status) in this population [7].

Only around 30% of patients in our study population received 2L therapy, which emphasizes the importance of selecting the most effective 1L treatment. This observation may reflect the poor condition of patients with disease progression after 1L treatment and/or perceptions of the risk-benefit ratio for 2L treatment options in the population.

Despite the increase in 1L treatment options for aNSCLC in recent years, patient outcomes remained poor in our study population, with a median OS of only 9.5 months, median TTD of 2.1 months, and rwTR in 29.0%. IO monotherapy was associated with improved patient outcomes, with a median OS of 14.0 months, median TTD of 5.3 months, and rwTR in 34.1%, supporting the clinical benefits reported in clinical trials when compared with chemotherapy [10–12]. OS and TTD were longest with targeted therapy (median 20.2 and 7.6 months, respectively), with rwTR rates identical to 1L IO monotherapy (34.1%). Overall, these data illustrate that more effective treatments are needed, particularly for patients who are ineligible for targeted therapy.

OS with 1L IO monotherapy in this real-world study was shorter than has been reported in clinical trials. For example, the median OS with 1L IO monotherapy was 14.0 months, compared with 26.3 months in the KEYNOTE-024 trial of 1L pembrolizumab [29]. In addition, median TTD and median TTNT with 1L IO monotherapy in our study were 5.3 months and 8.9 respectively, whereas the median PFS with pembrolizumab in KEYNOTE-024 was 10.3 months [10], although it should be noted that TTD captures discontinuations for all reasons, including progressive disease and toxicity. The shorter outcomes in this real-world study compared with randomized controlled trials should be interpreted with caution because of the differences between the heterogeneous population of patients treated in a clinical practice and the highly selected, “favorable-risk” populations eligible for clinical trials. For example, 24.3% of our population had an Eastern Cooperative Oncology Group performance status of ≥ 2, whereas these patients are typically excluded from oncology trials. The patient population in our study is also different from that assessed in other recent real-world studies in NSCLC, which focused on patients who continued treatment beyond 1L therapy [22] or included patients with early-stage NSCLC who received treatment with curative intent [30], which is not applicable to aNSCLC.

Our study has several acknowledged limitations. First, patient observation was limited with a median follow-up of 9.2 months; thus, outcome events (e.g. death for OS, treatment discontinuation for TTD) have not been observed in some patients and long-term survival data are immature. Second, only 3.1% of patients included had documented test results for oncogenic driver mutations or PD-L1 expression; thus, it was not possible to assess whether IO therapy or targeted therapy was used in the appropriate patient
population as defined by clinical guidelines. For example, it is possible that PD-L1 test results were available before *EGFR* or *ALK* test results, and as a result, physicians might have initiated IO therapy in patients with high PD-L1 expression who were subsequently found to have an *EGFR* or *ALK* genetic alteration. However, among patients who received 1L IO therapy and received 2L treatment in our study, no patient received an EGFR or ALK inhibitor as 2L treatment, suggesting that these patients were unlikely to have an *EGFR* mutation or *ALK* rearrangement. Similarly, although PD-L1 biomarker information was not available in our dataset, use of 1L IO monotherapy in the United Kingdom during the study period was restricted to patients with a PD-L1 tumor proportion score of $\geq 50\%$; thus, it is likely that only patients with a PD-L1 tumor proportion score $\geq 50\%$ received IO monotherapy in this population. Third, patients were assessed during a period when 1L IO monotherapy was first introduced. Outcomes of patients now treated with 1L IO monotherapy may reasonably be expected to be better than during the period of this study; patient selection, assessment of response and management of side effects have evolved as clinical experience increased.

In addition, a retrospective study such as this will inevitably provide a historical perspective on treatment pathways. Further real-world studies are needed to evaluate whether outcomes in aNSCLC have improved with the introduction of IO-based combination regimens or other novel therapies in clinical practice.

With regard to the generalizability of our results to the UK patient population, only sites with the capacity to participate were included, and 2 sites contributed more than half of patients. In addition, patients missing essential data were excluded, which may have differentially impacted hospitals with different follow-up capacities. For the analysis of TTD, the treatment end date in patients who discontinued treatment but were still alive was entered as the start date of the last treatment cycle, whereas the true treatment end date may have occurred several weeks later.

**Conclusions**

In this retrospective study of patients who received treatment for aNSCLC in UK clinical practice, 1L IO monotherapy was increasingly used between June 2016 and March 2018, but chemotherapy remained the most common 1L treatment. A minority of patients received 2L treatment. Patients treated with 1L IO monotherapy had a longer overall survival compared to those treated with 1L chemotherapy. OS was longest in patients who received 1L targeted therapy, suggesting that improved treatment options are needed for patients with aNSCLC without *EGFR*, *ALK* or *ROS1* alterations.

**Abbreviations**

1L, first line; 2L, second line; 3L, third line; 4L, fourth line; ALK, anaplastic lymphoma kinase; aNSCLC, advanced non-small cell lung cancer; EGFR, epidermal growth factor receptor; IO, immuno-oncology; NSCLC, non-small cell lung cancer; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; ROS1, ROS proto-oncogene 1; rwTR, real-world tumor response; TTD, time to treatment discontinuation; TtNT, time to next treatment.
Declarations

Ethics approval and consent to participate

Ethical approval was gained through Health Research Authority from the London - Bromley Research Ethics Committee. All data was pseudonymised at source, no patient identifiable data was collected and patient consent was therefore not required.

Consent for publication

All authors approve of submission of the manuscript and give their consent for publication.

Availability of data and materials

The data controllers and owners are the hospital trusts; the authors do not have permission to disseminate this data without approval of the owners.

Competing interests

JL has received honoraria and sponsorship from and participated in advisory boards for Roche, AstraZeneca, Pfizer, Boehringer Ingelheim, MSD, Bristol-Myers Squibb, and Lilly. CE has received travel grants from MSD, Roche, AstraZeneca, and Boehringer Ingelheim; consultancy fees from MSD, AstraZeneca, and Boehringer Ingelheim; and lecturer fees from Pfizer, AstraZeneca, and Roche. EH has participated in advisory board work for Roche, Tesaro, and GSK. TM has associations with MSD, Bristol-Myers Squibb, AstraZeneca, Roche, Boehringer Ingelheim, PharmaMar, and Tesaro. AC received an educational grant from Servier. SC has received speaker’s fees from Bristol-Myers Squibb. CP has received sponsorship to conferences from Boehringer Ingelheim and Roche and honoraria for talks and session chairing from Boehringer Ingelheim and Bristol-Myers Squibb. XZhuo was an employee of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA; a business of Merck KGaA, Darmstadt, Germany, when the analysis was conducted and is now an employee of Bristol-Myers Squibb. AD was an employee of Merck Serono Ltd., Feltham, United Kingdom; an affiliate of Merck KGaA, Darmstadt, Germany, when the analysis was conducted and is now an employee of Novartis. AA, PM, XZhang, and VP are current employees of Merck KGaA, Darmstadt, Germany. SK, JB, JC, LN, and VN have no relationships to disclose.

Funding

This work was supported by Merck KGaA, Darmstadt, Germany, as part of an alliance between Merck KGaA and Pfizer.

Authors’ contributions

Jason Lester: Conceptualization, Methodology, Writing - Review & Editing. Carles Escriu: Methodology, Writing - Review & Editing. Sarah Khan: Methodology, Writing - Review & Editing. Emma Hudson:
Acknowledgments

The authors would like to thank all the staff at the sites for supporting the study.

References

1. Royal College of Physicians. National Lung Cancer Audit annual report 2016 (for the audit period 2015). https://www.rcplondon.ac.uk/projects/outputs/nlca-annual-report-2016. Accessed 4 May 2020.

2. Cancer Research UK. Types of lung cancer. https://www.cancerresearchuk.org/about-cancer/lung-cancer/stages-types-grades/types. Accessed 4 May 2020.

3. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 Suppl 4:iv1-iv21.

4. Kaniski F, Enewold L, Thomas A, Malik S, Stevens JL, Harlan LC. Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010. Lung Cancer. 2017;103:66-74.

5. Azim HA, Jr., Elattar I, Loberiza FR, Jr., Azim H, Mok T, Ganti AK. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview. Lung Cancer. 2009;64(2):194-8.

6. Azim HA, Ganti AK, Elattar I, Azim H, Loberiza FR. Triplets vs. doublets in the management of advanced non-small cell lung cancer (NSCLC) using third generation chemotherapeutic agents: a meta-analysis. J Clin Oncol. 2007;25 Suppl 18:Abstract 7580.

7. Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP. Real-world treatment patterns, overall survival, and occurrence and costs of adverse events associated with first-line therapies for medicare patients 65 years and older with advanced non-small-cell lung cancer: a retrospective study. Clin Lung Cancer. 2018;19(5):e629-e645.
8. Cancer Research UK. Lung cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/lung-cancer#heading-Two. Accessed 4 May 2020.

9. Bernicker EH, Allen TC, Cagle PT. Update on emerging biomarkers in lung cancer. J Thorac Dis. 2019;11 Suppl 1:S81-S88.

10. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33.

11. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819-30.

12. Spigel D, De Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric ZM, Geater S, et al. IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Ann Oncol. 2019;30 Suppl 5:Abstract LBA78.

13. United Kindom Early Access to Medicines Schemes. https://www.gov.uk/government/publications/early-access-to-medicines-scheme-expired-scientific-opinions/expired-early-access-to-medicines-scheme-scientific-opinions. Accessed 27 Aug 2020.

14. National Institute for Health and Care Excellence (NICE). Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy: technology appraisal guidance [TA428]. www.nice.org.uk/guidance/ta428. Accessed 4 May 2020.

15. National Institute for Health and Care Excellence (NICE). Nivolumab for previously treated squamous non-small-cell lung cancer: technology Appraisal Guidance [TA483]. www.nice.org.uk/guidance/ta483. Accessed 4 May 2020.

16. National Institute for Health and Care Excellence (NICE). Atezolizumab for treating locally advanced or metastatic non-small-cell advanced or metastatic non-small-cell lung cancer after chemotherapy: technology appraisal guidance [TA520]. www.nice.org.uk/guidance/ta520. Accessed 4 May 2020.

17. National Institute for Health and Care Excellence (NICE). Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer: technology appraisal guidance [TA531]. www.nice.org.uk/guidance/ta531. Accessed 4 May 2020.

18. National Institute for Health and Care Excellence (NICE). Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer: technology appraisal guidance [TA557]. www.nice.org.uk/guidance/ta557. Accessed 4 May 2020.

19. National Institute for Health and Care Excellence (NICE). Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer: technology appraisal guidance [TA600]. www.nice.org.uk/guidance/ta600. Accessed 4 May 2020.
20. National Institute for Health and Care Excellence (NICE). Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer: technology appraisal guidance [TA584]. www.nice.org.uk/guidance/ta584. Accessed 4 May 2020.

21. Garrison LP, Jr., Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326-35.

22. Davies J, Patel M, Gridelli C, de Marinis F, Waterkamp D, McCusker ME. Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies. PLoS One. 2017;12(4):e0175679.

23. Snee M, Cheeseman S, Thompson M, Godden P, Sopwith W, Chaib C, Juarez-Garcia A, Lacoin L, Penrod JR, Hall G. Clinical characteristics and overall survival of patients diagnosed with non-small cell lung cancer (NSCLC) between 2006 and 2017 in routine clinical practice: a retrospective analysis of a UK hospital database. Lung Cancer. 2018;115 Suppl 1:S38.

24. Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, Kluetz PG, Oxnard GR, Pazdur R. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30(5):830-8.

25. Wang M, Dhokia P, Menon S, Martindale B. First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK. Ann Oncol. 2018;29:x22.

26. Snee M, Cheeseman S, Thompson M, Lacoin L, Sopwith W, Godden P, Chaib C, Daumont M, Penrod JR, O'Donnell J, et al. Treatment patterns in patients with stage IIIIB-IV NSCLC in clinical practice: retrospective analysis of a UK trust database. Thorax. 2018;73 Suppl 4:A145-A146 [abstract P182].

27. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.

28. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50.

29. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. KEYNOTE-024 3-year survival update: pembrolizumab vs platinum-based chemotherapy for advanced non–small-cell lung cancer. J Thorac Oncol. 2019;14(10):S243 [abstract OA214.201].

30. Snee M, Cheeseman S, Thompson M, Riaz M, Lacoin L, Sopwith W, Chaib C, Daumont M, Penrod JR, O’Donnell JC, et al. Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: a real-oncology database analysis from the I-O Optimise initiative. Ann Oncol. 2019;30:ii14-ii15.